5 assets in NTRK Fusion Positive Cancer

Therapeutic assets addressing NTRK Fusion Positive Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
bay2757556 NTRK Fusion Positive Cancer	Bayer	P2	BB (70)
Larotrectinib NTRK Fusion Positive Cancer	Bayer	P1/2	BB (65)
cg001419 tablets NTRK Fusion Positive Cancer	Cullgen (Shanghai),Inc	P1/2	CCC (48)
Icp-723 NTRK Fusion Positive Cancer	Beijing InnoCare Pharma Tech Co., Ltd.	P1/2	NR ()
vc004 NTRK Fusion Positive Cancer	Jiangsu vcare pharmaceutical technology co., LTD	P1	NR ()